Human Complement from Innovative Research was used in the following study:
Lukmanee Tradtrantip, Tianjiao Duan, Michael R. Yeaman, Alan S. Verkman
Journal of Neuroinflammation
December 2019, 16:57
"... Neuromyelitis optica spectrum disorder (herein called NMO) is an inflammatory demyelinating disease that can be initiated by binding of immunoglobulin G autoantibodies (AQP4-IgG) to aquaporin-4 on astrocytes, causing complement-dependent cytotoxicity (CDC) and downstream inflammation. The increased NMO pathology in rodents deficient in complement regulator protein CD59 following passive transfer of AQP4-IgG has suggested the potential therapeutic utility of increasing the expression of complement regulator proteins...Human complement was purchased from Innovative Research (Novi, MI)..."
